Literature DB >> 22632371

Quality of life in Graves' ophthalmopathy.

Wilmar M Wiersinga1.   

Abstract

General health-related quality-of-life (QoL) questionnaires (MOS SF-24 and SF-36) and the more sensitive disease-specific QoL questionnaire (GO-QoL) both indicate substantial impairment of quality of life in patients with Graves' ophthalmopathy (GO). The GO-QoL contains 8 questions on visual functioning and 8 questions on appearance; answers on each subscale are transformed to scores ranging from 0 (worst) to 100 (best). The minimal clinically important difference in scores is ≥10 points for invasive therapies, but a change of 6 points on one of both subscales is already perceived by patients as beneficial and associated with an important change in daily functioning. The GO-QoL is well validated, widely used, and available in eight languages. The GO-QoL is recommended as an independent primary outcome measure in randomized clinical trials. Incorporating the GO-QoL in the routine assessment of GO in daily clinical practice is also recommended: although unproven, it is likely to improve the quality of care by identifying patients who are in need for psychological support in order to address poor psychosocial functioning and low self-esteem.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22632371     DOI: 10.1016/j.beem.2011.11.001

Source DB:  PubMed          Journal:  Best Pract Res Clin Endocrinol Metab        ISSN: 1521-690X            Impact factor:   4.690


  20 in total

Review 1.  Graves' orbitopathy: imperfect treatments for a rare disease.

Authors:  Luigi Bartalena
Journal:  Eur Thyroid J       Date:  2013-11-20

2.  Management of patients with dysthyroid optic neuropathy treated with intravenous corticosteroids and/or orbital decompression surgery.

Authors:  Sandra Rezar-Dreindl; Andrea Papp; Arnulf Baumann; Thomas Neumayer; Katharina Eibenberger; Eva Stifter; Ursula Schmidt-Erfurth
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-06-22       Impact factor: 3.535

Review 3.  Ocular surface disease in thyroid eye disease: A narrative review.

Authors:  Harkaran S Rana; Sruti S Akella; Carson E Clabeaux; Zachary P Skurski; Vinay K Aakalu
Journal:  Ocul Surf       Date:  2022-02-12       Impact factor: 6.268

4.  Fat-removal orbital decompression for disfiguring proptosis associated with Graves' ophthalmopathy: safety, efficacy and predictability of outcomes.

Authors:  Emmy Y Li; Tracy Y Kwok; Andy C Cheng; Alex C Wong; Hunter K Yuen
Journal:  Int Ophthalmol       Date:  2014-04-29       Impact factor: 2.031

5.  Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study.

Authors:  Mario Salvi; Guia Vannucchi; Nicola Currò; Irene Campi; Danila Covelli; Davide Dazzi; Simona Simonetta; Claudio Guastella; Lorenzo Pignataro; Sabrina Avignone; Paolo Beck-Peccoz
Journal:  J Clin Endocrinol Metab       Date:  2014-12-15       Impact factor: 5.958

6.  Description and evaluation of the first national patient and public involvement day for thyroid eye disease in the United Kingdom.

Authors:  Henry B Smith; Carol Porteous; Catey Bunce; Karen Bonstein; Janis Hickey; Colin M Dayan; Gill Adams; Geoff E Rose; Daniel G Ezra
Journal:  Thyroid       Date:  2014-07-21       Impact factor: 6.568

7.  Intraorbital injection of rituximab versus high dose of systemic glucocorticoids in the treatment of thyroid-associated orbitopathy.

Authors:  Gustavo Savino; Erika Mandarà; Mariangela Gari; Remo Battendieri; Salvatore Maria Corsello; Alfredo Pontecorvi
Journal:  Endocrine       Date:  2014-06-01       Impact factor: 3.633

Review 8.  Peroxisome Proliferator-Activated Receptor- γ in Thyroid Autoimmunity.

Authors:  Silvia Martina Ferrari; Poupak Fallahi; Roberto Vita; Alessandro Antonelli; Salvatore Benvenga
Journal:  PPAR Res       Date:  2015-02-01       Impact factor: 4.964

9.  Thyroid Stimulating but Not Blocking Autoantibodies Are Highly Prevalent in Severe and Active Thyroid-Associated Orbitopathy: A Prospective Study.

Authors:  E Kampmann; T Diana; M Kanitz; D Hoppe; G J Kahaly
Journal:  Int J Endocrinol       Date:  2015-06-28       Impact factor: 3.257

10.  Original endoscopic orbital decompression of lateral wall through hairline approach for Graves' ophthalmopathy: an innovation of balanced orbital decompression.

Authors:  Yi Gong; Jiayang Yin; Boding Tong; Jingkun Li; Jiexi Zeng; Zhongkun Zuo; Fei Ye; Yongheng Luo; Jing Xiao; Wei Xiong
Journal:  Ther Clin Risk Manag       Date:  2018-03-26       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.